Literature DB >> 26660428

Emerging therapeutic drugs for AML.

Eytan M Stein1, Martin S Tallman1.   

Abstract

Multiple new drugs are being developed to treat acute myeloid leukemia (AML), including novel formulations of traditional chemotherapy-antibody drug conjugates and agents that target specific mutant enzymes. Next-generation sequencing has allowed us to discover the genetic mutations that lead to the development and clinical progression of AML. Studies of clonal hierarchy suggest which mutations occur early and dominate. This has led to targeted therapy against mutant driver proteins as well as the development of drugs such as CPX-351 and SGN-CD33A whose mechanisms of action and efficacy may not be dependent on mutational complexity. In this brief review, we discuss drugs that may emerge as important for the treatment of AML in the next 10 years.
© 2016 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26660428      PMCID： PMC4915807          DOI： 10.1182/blood-2015-07-604538

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  52 in total

1.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

Authors:  Scott R Daigle; Edward J Olhava; Carly A Therkelsen; Aravind Basavapathruni; Lei Jin; P Ann Boriack-Sjodin; Christina J Allain; Christine R Klaus; Alejandra Raimondi; Margaret Porter Scott; Nigel J Waters; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

2.  The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations.

Authors:  Frederick R Appelbaum; Kenneth J Kopecky; Martin S Tallman; Marilyn L Slovak; Holly M Gundacker; Haesook T Kim; Gordon W Dewald; Hagop M Kantarjian; Sherry R Pierce; Elihu H Estey
Journal:  Br J Haematol       Date:  2006-08-25       Impact factor: 6.998

3.  Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.

Authors:  Farhad Ravandi; Ellen K Ritchie; Hamid Sayar; Jeffrey E Lancet; Michael D Craig; Norbert Vey; Stephen A Strickland; Gary J Schiller; Elias Jabbour; Harry P Erba; Arnaud Pigneux; Heinz-August Horst; Christian Recher; Virginia M Klimek; Jorge Cortes; Gail J Roboz; Olatoyosi Odenike; Xavier Thomas; Violaine Havelange; Johan Maertens; Hans-Günter Derigs; Michael Heuser; Lloyd Damon; Bayard L Powell; Gianluca Gaidano; Angelo-Michele Carella; Andrew Wei; Donna Hogge; Adam R Craig; Judith A Fox; Renee Ward; Jennifer A Smith; Gary Acton; Cyrus Mehta; Robert K Stuart; Hagop M Kantarjian
Journal:  Lancet Oncol       Date:  2015-07-30       Impact factor: 41.316

4.  Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.

Authors:  Aniruddha J Deshpande; Liying Chen; Maurizio Fazio; Amit U Sinha; Kathrin M Bernt; Deepti Banka; Stuart Dias; Jenny Chang; Edward J Olhava; Scott R Daigle; Victoria M Richon; Roy M Pollock; Scott A Armstrong
Journal:  Blood       Date:  2013-01-29       Impact factor: 22.113

Review 5.  Important milestones in acute leukemia in 2013.

Authors:  Jacob M Rowe
Journal:  Best Pract Res Clin Haematol       Date:  2013-10-16       Impact factor: 3.020

6.  Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.

Authors:  Jorge E Cortes; Stuart L Goldberg; Eric J Feldman; David A Rizzeri; Donna E Hogge; Melissa Larson; Arnaud Pigneux; Christian Recher; Gary Schiller; Krzysztof Warzocha; Hagop Kantarjian; Arthur C Louie; Jonathan E Kolitz
Journal:  Cancer       Date:  2014-09-15       Impact factor: 6.860

7.  Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.

Authors:  Mark A Dawson; Rab K Prinjha; Antje Dittmann; George Giotopoulos; Marcus Bantscheff; Wai-In Chan; Samuel C Robson; Chun-wa Chung; Carsten Hopf; Mikhail M Savitski; Carola Huthmacher; Emma Gudgin; Dave Lugo; Soren Beinke; Trevor D Chapman; Emma J Roberts; Peter E Soden; Kurt R Auger; Olivier Mirguet; Konstanze Doehner; Ruud Delwel; Alan K Burnett; Phillip Jeffrey; Gerard Drewes; Kevin Lee; Brian J P Huntly; Tony Kouzarides
Journal:  Nature       Date:  2011-10-02       Impact factor: 49.962

8.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.

Authors:  Peter Paschka; Richard F Schlenk; Verena I Gaidzik; Marianne Habdank; Jan Krönke; Lars Bullinger; Daniela Späth; Sabine Kayser; Manuela Zucknick; Katharina Götze; Heinz-A Horst; Ulrich Germing; Hartmut Döhner; Konstanze Döhner
Journal:  J Clin Oncol       Date:  2010-06-21       Impact factor: 50.717

9.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.

Authors:  Patrick S Ward; Jay Patel; David R Wise; Omar Abdel-Wahab; Bryson D Bennett; Hilary A Coller; Justin R Cross; Valeria R Fantin; Cyrus V Hedvat; Alexander E Perl; Joshua D Rabinowitz; Martin Carroll; Shinsan M Su; Kim A Sharp; Ross L Levine; Craig B Thompson
Journal:  Cancer Cell       Date:  2010-02-18       Impact factor: 38.585

10.  REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.

Authors:  Robert K Stuart; Larry D Cripe; Michael B Maris; Maureen A Cooper; Richard M Stone; Shaker R Dakhil; Francesco Turturro; Wendy Stock; James Mason; Paul J Shami; Stephen A Strickland; Luciano J Costa; Gautam Borthakur; Glenn C Michelson; Judith A Fox; Richard D Leavitt; Farhad Ravandi
Journal:  Br J Haematol       Date:  2014-11-17       Impact factor: 6.998
View more
  76 in total

1.  Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation.

Authors:  Su-Fern Tan; Wendy Dunton; Xin Liu; Todd E Fox; Samy A F Morad; Dhimant Desai; Kenichiro Doi; Mark R Conaway; Shantu Amin; David F Claxton; Hong-Gang Wang; Mark Kester; Myles C Cabot; David J Feith; Thomas P Loughran
Journal:  J Lipid Res       Date:  2019-04-08       Impact factor: 5.922

2.  Human AML-iPSCs Reacquire Leukemic Properties after Differentiation and Model Clonal Variation of Disease.

Authors:  Mark P Chao; Andrew J Gentles; Susmita Chatterjee; Feng Lan; Andreas Reinisch; M Ryan Corces; Seethu Xavy; Jinfeng Shen; Daniel Haag; Soham Chanda; Rahul Sinha; Rachel M Morganti; Toshinobu Nishimura; Mohamed Ameen; Haodi Wu; Marius Wernig; Joseph C Wu; Ravindra Majeti
Journal:  Cell Stem Cell       Date:  2017-01-12       Impact factor: 24.633

Review 3.  From genomics to targeted treatment in haematological malignancies: a focus on acute myeloid leukaemia.

Authors:  Niels Asger Jakobsen; Paresh Vyas
Journal:  Clin Med (Lond)       Date:  2018-04-01       Impact factor: 2.659

4.  Early mortality and survival in older adults with acute myeloid leukemia.

Authors:  Manisha Pant; Vijaya Raj Bhatt
Journal:  Int J Hematol Oncol       Date:  2017-11-20

5.  Acute myeloid leukemia in very old patients.

Authors:  Vladimir Lj Lazarevic; Anders Bredberg; Fryderyk Lorenz; Emma Öhlander; Petar Antunovic; Jörg Cammenga; Lovisa Wennström; Lars Möllgård; Stefan Deneberg; Åsa Derolf; Martin Höglund; Gunnar Juliusson
Journal:  Haematologica       Date:  2018-06-28       Impact factor: 9.941

Review 6.  Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?

Authors:  Maximilian Stahl; Benjamin Y Lu; Tae Kon Kim; Amer M Zeidan
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

Review 7.  Selected biological issues affecting relapse after stem cell transplantation: role of T-cell impairment, NK cells and intrinsic tumor resistance.

Authors:  Marcel van den Brink; Markus Uhrberg; Lorenz Jahn; John F DiPersio; Michael A Pulsipher
Journal:  Bone Marrow Transplant       Date:  2018-01-24       Impact factor: 5.483

Review 8.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.

Authors:  Hartmut Döhner; Elihu Estey; David Grimwade; Sergio Amadori; Frederick R Appelbaum; Thomas Büchner; Hervé Dombret; Benjamin L Ebert; Pierre Fenaux; Richard A Larson; Ross L Levine; Francesco Lo-Coco; Tomoki Naoe; Dietger Niederwieser; Gert J Ossenkoppele; Miguel Sanz; Jorge Sierra; Martin S Tallman; Hwei-Fang Tien; Andrew H Wei; Bob Löwenberg; Clara D Bloomfield
Journal:  Blood       Date:  2016-11-28       Impact factor: 22.113

9.  Gemtuzumab ozogamicin for treatment of newly diagnosed CD33-positive acute myeloid leukemia.

Authors:  Mohammed Gbadamosi; Soheil Meshinchi; Jatinder K Lamba
Journal:  Future Oncol       Date:  2018-07-24       Impact factor: 3.404

Review 10.  The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.

Authors:  Su-Fern Tan; Jennifer M Pearson; David J Feith; Thomas P Loughran
Journal:  Expert Opin Ther Targets       Date:  2017-05-02       Impact factor: 6.902
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.